Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Findings from a Johns Hopkins Medicine research study published today in JAMA Network Open provide strong evidence that people who are pregnant and have been infected with SARS-CoV-2 (the virus that causes COVID-19) can safely take the antiviral drug Paxlovid to reduce the possibility of severe disease.

Pregnant people can safely take Paxlovid to reduce the possibility of severe COVID-19, study shows

Tonix Pharmaceuticals Holding Corp.   today announced data from its fully human anti-SARS-CoV-2 monoclonal antibody platform in an oral presentation delivered by Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, at the World Antiviral Congress 2022 in San Diego, Calif.

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

The ACP has released living, rapid practice points summarizing the best available evidence on the treatment of adults with confirmed mild or moderate COVID-19 in an outpatient setting.“Management of COVID-19 in the outpatient setting continues to evolve as new data emerges on SARS-CoV-2 variants and the availability of newer treatments,” ACP President Ryan D. Mire, MD, MACP, said in a press release. “These living practice points will be a valuable clinical resource for physicians and the rest of the health care community in treating patients in the outpatient setting, as

ACP releases living practice points on COVID-19 treatment in outpatient settings

Pregnant women can safely take the antiviral drug Paxlovid to reduce the risk of serious COVID-19 pregnancy or fetal complications, according to a small study published yesterday in JAMA Network Open.

antiviral news

Press Releases in the global landscape